The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Transdermal Nicotine for Active Ulcerative Colitis
Abstract
BACKGROUND: Ulcerative colitis is largely a disease of nonsmokers. Because anecdotal reports suggest that smoking and nicotine may improve the symptoms of the disease, we examined the effect of nicotine as a supplemental treatment for ulcerative colitis. METHODS: We treated 72 patients with active ulcerative colitis with either transdermal nicotine patches or placebo patches for six weeks in a randomized, double-blind study. Incremental doses of nicotine were given; most patients tolerated doses of 15 to 25 mg per 24 hours. All the patients had been taking mesalamine, and 12 were receiving low doses of glucocorticoids; these medications were continued without change during the study. Clinical, sigmoidoscopic, and histologic assessments were made at base line and at the end of the study; symptoms were recorded daily on a diary card, and the clinician made a global assessment. Side effects and plasma nicotine and cotinine concentrations were monitored throughout the study. RESULTS: Seventeen of the 35 patients in the nicotine group had complete remissions, as compared with 9 of the 37 patients in the placebo group (P = 0.03). The patients in the nicotine group had greater improvement in the global clinical grade of colitis (P < 0.001) and the histologic grade (P = 0.03), lower stool frequency (a difference of 1.6 stools daily; P = 0.008), less abdominal pain (P = 0.05), and less fecal urgency (P = 0.009). More patients in the nicotine group had side effects (23, vs. 11 in the placebo group; P = 0.002), the most common of which were nausea, lightheadedness, headache, and sleep disturbance. Withdrawals due to ineffective therapy were more common in the placebo group (3 vs. 8, P = 0.12). CONCLUSIONS: The addition of transdermal nicotine to conventional maintenance therapy improves symptoms in patients with ulcerative colitis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“early clinical observations suggesting that cigarette smoking might be beneficial to patients with ulcerative colitis led to randomized clinical trials of nicotine administration to patients that demonstrated significant benefit in a subset of patients (76,77).”
From Physiology and immunology of the cholinergic antiinflammatory pathway (2007) · cites this paper as [76]
Citations
Cites
Statistical Methods for Rates and Proportions, 2nd ed
GROVE, W. A. (1981) · American Journal of Psychiatry · doi:10.1176/ajp.138.12.1644-a · Cited by 3,756
Cortisone in Ulcerative Colitis
Truelove, S. C., & Witts, L. J. (1955) · BMJ · doi:10.1136/bmj.2.4947.1041 · Cited by 2,793
Comparison of tests used to distinguish smokers from nonsmokers
Jarvis, M. J., Tunstall-Pedoe, H., Feyerabend, C., Vesey, C., & Saloojee, Y. (1987) · American Journal of Public Health · doi:10.2105/ajph.77.11.1435 · Cited by 994
Self-citationVariation Between Observers in Describing Mucosal Appearances in Proctocolitis
Baron, J. H., Connell, A. M., & Lennard‐Jones, J. E. (1964) · BMJ · doi:10.1136/bmj.1.5375.89 · Cited by 607
Daily intake of nicotine during cigarette smoking
Benowitz, N. L., & Jacob, P. (1984) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1984.67 · Cited by 502
Biopsy Studies in Ulcerative Colitis
Truelove, S. C., & Richards, W. C. D. (1956) · BMJ · doi:10.1136/bmj.1.4979.1315 · Cited by 394
Non-smoking: a feature of ulcerative colitis.
Harries, A. D., Baird, A., & Rhodes, J. (1982) · BMJ · doi:10.1136/bmj.284.6317.706 · Cited by 328
Self-citationFeyerabend, C., & Russell, M. A. (1990) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1990.tb06592.x · Cited by 309
Self-citationA Double-Blind Trial of a 16-Hour Transdermal Nicotine Patch in Smoking Cessation
Tønnesen, P., Nørregaard, J., Simonsen, K., & Säwe, U. (1991) · New England Journal of Medicine · doi:10.1056/nejm199108013250503 · Cited by 296
Cigarette Smoking: A Dependence on High-Nicotine Boli
Russell, M. A. H., & Feyerabend, C. (1978) · Drug Metabolism Reviews · doi:10.3109/03602537808993776 · Cited by 253
Self-citation
Research works printed but not linked: 6
- Roberts CJ, 1982, BMJ, 285, 440
- Srivastava ED, 1991, Eur J Gastroenterol, 3, 815
- Allen A, Bell A, McQueen S. Mucus and mucosal protection. In: Allen A, Flemstrom G, Garner A, Silen W, Turnberg LA, eds. Mechanisms of mucosal protection in the upper gastrointestinal tract. New York: Raven Press, 1984:195-201.
- Cope GF, 1986, Gut, 27, A618
- Dubois JP, 1989, Methods Find Exp Clin Pharmacol, 11, 187
- Russell MAH. Nicotine intake and its control over smoking. In: Wonnacott S, Russell MAH, Stolerman IP, eds. Nicotine psychopharmacology: molecular, cellular, and behavioural aspects. Oxford, England: Oxford University Press, 1990:374-418.
Cited by
Sorted by citations
Items 301–400 of 505
Ashley, M. J. (1997) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/1997/539451 · Cited by 16
Gibson, P. R. (1994) · BioDrugs · doi:10.1007/bf03259263 · Cited by 16
Cholinergic Regulation of Inflammation
Czura, C. J., Rosas‐Ballina, M., & Tracey, K. J. (2007) · Elsevier eBooks · doi:10.1016/b978-012088576-3/50007-1 · Cited by 16
Inflammatory Bowel Disease Management
Rhodes, J., Thomas, G. A. O., & Evans, B. K. (1997) · Drugs · doi:10.2165/00003495-199753020-00001 · Cited by 15
Self-citationHanauer, S. B., & Schulman, M. I. (1995) · Gastroenterology Clinics of North America · doi:10.1016/s0889-8553(21)00209-0 · Cited by 15
Zyoud, S. H. (2018) · Globalization and Health · doi:10.1186/s12992-018-0335-z · Cited by 14
“, [62] “Transdermal nicotine for active ulcerative colitis” New England Journal of Medicine 381”
BackgroundGreenstein, R. J., Su, L., & Brown, S. T. (2010) · Digestive Diseases and Sciences · doi:10.1007/s10620-010-1301-7 · Cited by 14
“In intriguing contrast, the clinical course of ulcerative colitis (UC) is ameliorated by use of tobacco [3, 6, 7], or nicotine [8, 9], one of tobacco’s 4,000 constituent molecules [10, 11].”
BackgroundSmoking Is a Risk Factor for Relapse of Antimyeloperoxidase Antibodies–Associated Vasculitis
Yamaguchi, M., Ando, M., Katsuno, T., Tsuboi, N., & Maruyama, S. (2018) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0000000000000737 · Cited by 14
Nicotine Treatment in Ulcerative Colitis
Rhodes, J., & Thomas, G. A. O. (1995) · Drugs · doi:10.2165/00003495-199549020-00001 · Cited by 14
Self-citationThe 100 classic papers in ulcerative colitis: a bibliometric analysis
Connelly, T. M., Devane, L., Kelly, J. C., Wrafter, P. F., & Messaris, E. (2016) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2016.1216786 · Cited by 13
“43 506 Sartor a [94] 93 338 Garrett [95] 44 498 Madsen [96] 94 337 Bernstein [97] 45 495 Edwards [98] 95 337 Pullan [99] 46 495 Edwards [100] 96 337 Rubin [101] 47 474 Braegger [102] 97 336 Truelove [103] 48 473 Jostins [2] 98 334 Lennard-Jones [104] 49 473 Rutter [105] 99 333 Toruner [106] 50 469 Itzkowitz [107] 100…”
Elevated IL-17A Levels in Early Stages of Bladder Cancer Regardless of Smoking Status
Doroudchi, M., Saidi, M., Malekzadeh, M., Golmoghaddam, H., Khezri, A., & Ghaderi, A. A. (2013) · Future Oncology · doi:10.2217/fon.12.180 · Cited by 13
“Clinical data, however, also support an anti-inflammatory role for nicotine [39–41].”
BackgroundUlcerative colitis: prevention of relapse
Naganuma, M., Sakuraba, A., & Hibi∥, T. (2013) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/egh.13.18 · Cited by 13
Expression of Beclin1 in the colonic mucosa tissues of patients with ulcerative colitis.
Hao, X., Yang, B., Liu, X., Yang, H., & Liu, X.-S. (2015) · PubMed · Cited by 13
Treatment of classic Kaposi sarcoma with a nicotine dermal patch: a phase II clinical trial
Jj, G., Scoppio, B., Pfeiffer, R. M., Neve, L., Federici, A., Long, L., Dolan, B., Brambati, M., Bellinvia, M., Lauria, C., et al. (2008) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2008.02720.x · Cited by 13
A Cholinergic Agonist Attenuates Endotoxin-Induced Uveitis in Rats
Chi, Z., Hayasaka, S., Zhang, X.-Y., Cui, H.-S., & Hayasaka, Y. (2007) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.06-0644 · Cited by 14
Nicotine potentiates vascular endothelial growth factor expression in balloon-injured rabbit aortas
Yao, Z., Ruixing, Y., Qi, B., & Wu, J. (2008) · Growth Factors · doi:10.1080/08977190802292640 · Cited by 13
“2000), ulcerative colitis (Pullan et al. 1994; Scheid et al. 2000), Parkinson’s disease (Court et al.”
BackgroundMethodThe Effect of Mesalamine and Nicotine in the Treatment of Inflammatory Bowel Disease
Bonapace, C. R., & Mays, D. A. (1997) · Annals of Pharmacotherapy · doi:10.1177/106002809703100719 · Cited by 13
Nicotine for Colitis -- The Smoke Has Not Yet Cleared
Hanauer, S. B. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403243301209 · Cited by 13
Louvet, B., Buisine, M., Desreumaux, P., Tremaine, W. J., Aubert, J., Porchet, N., Capron, M., Cortot, A., Colombel, J., & Sandborn, W. J. (2007) · Inflammatory Bowel Diseases · doi:10.1002/ibd.3780050306 · Cited by 13
Jaakkola, K., Knuuti, J., Söderlund, K., Saraste, A., Jalkanen, S., & Voipio-Pulkki, L. (1998) · JIM - Journal of Immunological Methods · doi:10.1016/s0022-1759(98)00045-3 · Cited by 12
Altarescu, G., Rachmilewitz, D., & Zevin, S. (2011) · PubMed · Cited by 11
Therapeutic Applications of Nicotinic Stimulation: Successes, Failures, and Future Prospects
NEWHOUSE, P. A. (2018) · Nicotine & Tobacco Research · doi:10.1093/ntr/nty189 · Cited by 11
Sun, Y. P., Wang, H. H., He, Q., & Cho, C. H. (2007) · Digestion · doi:10.1159/000112643 · Cited by 12
“However, no direct evidence shows where and how cigarette smoking is involved in IBD.Nicotine is the main component of cigarette smoking. Two randomized, placebo-controlled trials have shown significant clinical benefit from transdermal nicotine, with the remission rate doubled after treatment for 6 weeks [”
BackgroundProblematic proctitis and distal colitis
Gionchetti, P., Rizzello, F., Morselli, C., & Campieri, M. (2004) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2004.02049.x · Cited by 11
Watson, J., & Lewis, R. A. (1995) · Respiratory Medicine · doi:10.1016/0954-6111(95)90235-x · Cited by 11
Depression, smoking, and nicotine: Toward a bioinformational situation by trait model
Gilbert, D. G. (1996) · Drug Development Research · doi:10.1002/(sici)1098-2299(199607/08)38:3/4 · Cited by 25
Wolf, R., Orion, E., Matz, H., Maitra, S., & Rowland‐Payne, C. (2004) · Journal of Cosmetic Dermatology · doi:10.1111/j.1473-2130.2004.00069.x · Cited by 11
Nicotine and gastrointestinal disease
Thomas, G. A. O., Rhodes, J., & Green, J. (1996) · QJM · doi:10.1093/qjmed/89.7.485 · Cited by 11
Self-citationInflammatory Bowel Disease: a New Assessment
Gitnick, G. (1996) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365529609094756 · Cited by 10
Seeking approval: present and future therapies for pemphigus vulgaris.
Mao, X., & Payne, A. S. (2008) · PubMed · Cited by 10
Haghighi, D., & Lashner, B. A. (2004) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2004.02.008 · Cited by 10
“of a transdermal patch or as chewing gum, has successfully treated ulcerative colitis, especially in former smokers, by a mechanism that has yet to be elucidated [16,17].”
BackgroundThe changing faces of Crohn’s disease and ulcerative colitis
Ekbom, A. (2007) · Springer eBooks · doi:10.1007/0-387-25808-6_2 · Cited by 10
“The consistency of these results has even led to the initiation of pharmacologic therapy by nicotine, mostly as patches, which in most instances have shown beneficial effects [95].”
BackgroundLong COVID – a critical disruption of cholinergic neurotransmission?
Leitzke, M., Roach, D. T., Hesse, S., Schönknecht, P. O. D., Becker, G., Rullmann, M., Sattler, B., & Sabri, O. (2025) · Bioelectronic Medicine · doi:10.1186/s42234-025-00167-8 · Cited by 9
Vincenzo, F. D., D’Onofrio, A. M., GAUDIO, A. D., Chiera, E., Ferrajoli, G. F., Pesaresi, F., Simonetti, A., Mazza, M., Kotzalidis, G. D., Pettorruso, M., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136514 · Cited by 9
“On the other hand, increasing para-sympathetic organ drive using a nicotine patch has been shown to improve the inflammatory state in patients with UC [101].”
Smoking and nicotine in inflammatory bowel disease: good or bad for cytokines?
Zijlstra, F. J. (1998) · Mediators of Inflammation · doi:10.1080/09629359891072 · Cited by 9
“Transdermal nicotine for active UC during 6 weeks has been proven to be effective as additional treatment regimen besides the low-dose continuation of corticosteroids and/or 5-amino-salicylic acid (5-ASA).(19) Clinical observations following diary instructions revealed a significant decreased disease activity score (D…”
New treatments for inflammatory bowel disease
Rampton, D. S. (1998) · World Journal of Gastroenterology · doi:10.3748/wjg.v4.i5.369 · Cited by 9
Zhong, Y. (2005) · World Journal of Gastroenterology · doi:10.3748/wjg.v11.i28.4435 · Cited by 9
“... abnormality, epithelial cell regeneration, atypical hyperplasia, goblet cell depletion (GCD) and Paneth cell metaplasia (PCM); inflammatory cell infiltration in mucosal epithelium such as lymphocyte hyperplasia, lymphoid follicular formation, eosinophils (Eos) and plasmacytes; cellular stromal lesions including gr…”
BackgroundAn Overview of Nicotine Use Disorders for Alcohol/Drug Abuse Clinicians
Hughes, J. R. (1996) · American Journal on Addictions · doi:10.1111/j.1521-0391.1996.tb00310.x · Cited by 10
Medical approaches and future options in chronic active ulcerative colitis
Siveke, J. T., & Folwaczny, C. (2004) · International Journal of Colorectal Disease · doi:10.1007/s00384-003-0569-x · Cited by 9
“In mildly to moderately active ulcerative colitis, positive results were also obtained in trials evaluating the use of transdermal nicotine [112, 113, 114, 115].”
BackgroundBerre, C. L., Loy, L., Lönnfors, S., Avedano, L., & Piovani, D. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i29.4343 · Cited by 8
Transdermal Nicotine as a Treatment Option for Ulcerative Colitis: A Review
Kannichamy, V., Antony, I., Mishra, V., Banerjee, A., Gandhi, A. B., Kaleem, I., Alexander, J., Hisbulla, M., & Khan, S. (2020) · Cureus · doi:10.7759/cureus.11096 · Cited by 8
“, 1994 [17] Randomized control trial 72 placebo Six weeks The addition of transdermal nicotine to conventional maintenance therapy improves symptoms in patients with ulcerative colitis.”
BackgroundMolfino, A., Logorelli, F., Citro, G., Bertini, G., Ramaccini, C., Bollea, M. R., Fanelli, F. R., & Laviano, A. (2011) · Nutrition and Cancer · doi:10.1080/01635581.2011.530736 · Cited by 8
“This could be important when translating these results into humans, since in most clinical trials involving patients with chronic and moderate inflammation (eg, ulcerative colitis), nicotine's dose ranged 15–25 mg/d ( 24 ).”
BackgroundManagement of refractory inflammatory bowel disease
Solem, C. A., & Loftus, E. V. (2004) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2004.02.011 · Cited by 8
“Transdermal nicotine may be efficacious for the induction of remission in mild to moderately active UC, but is ineffective for maintenance [96–101].”
BackgroundBock, K., Plaaß, C., Coger, V., Peck, C., Reimers, K., Stukenborg-Colsman, C. M., & Claaßen, L. (2016) · SAGE Open Medicine · doi:10.1177/2050312116637529 · Cited by 8
The changing faces of Crohn’s disease and ulcerative colitis
Ekbom, A. (2003) · Springer eBooks · doi:10.1007/978-1-4020-3477-0_2 · Cited by 8
On smoking, rats, and inflammatory bowel disease
Rachmilewitz, D. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70360-4 · Cited by 8
Verhaeghe, C., Talikka, M., Sewer, A., Sierro, N., Auberson, M., Peric, D., Bornand, D., Dulize, R., Guedj, E., Nef, P., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076419 · Cited by 8
Sussman, E. S., Kellner, C. P., McDowell, M. M., Bruce, S. S., Heuts, S. G., Zhuang, Z., Bruce, R. A., Claassen, J., & Connolly, E. S. (2013) · Neurosurgical FOCUS · doi:10.3171/2013.2.focus1315 · Cited by 7
Penhasi, A., Gomberg, M., & Shalev, D. E. (2020) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2020.101583 · Cited by 7
Relationship between Smoking, Nicotine and Ulcerative Colitis
Thomas, G. A. O., & Rhodes, J. (1995) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-7445-8_37 · Cited by 7
Self-citationBencherif, M., Byrd, G. D., Caldwell, W. S., Hayes, J. R., & Lippiello, P. M. (1997) · CNS Drug Reviews · doi:10.1111/j.1527-3458.1997.tb00331.x · Cited by 7
9 Management of the first presentation of severe acute colitis
Leiper, K., London, I. J., & Rhodes, J. M. (1997) · Baillière s Clinical Gastroenterology · doi:10.1016/s0950-3528(97)90058-0 · Cited by 7
Self-citation(1997) · Annals of Pharmacotherapy · doi:10.1177/106002809703100720 · Cited by 7
Involvement of Neuronal Nicotinic Receptors in Disease
Clementi, F., COURT, J. A., & Perry, E. A. (2000) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-57079-7_25 · Cited by 7
Inflammatory bowel disease: Short- and long- term treatments
Bickston, S. J., & Cominelli, F. (1998) · Disease-a-Month · doi:10.1016/s0011-5029(98)90008-6 · Cited by 7
Personalized (N-of-1) Clinical Trials for Inflammatory Bowel Disease: Opportunities and Challenges
Honap, S., Zou, G., Danese, S., Peyrin‐Biroulet, L., & Jairath, V. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.08.028 · Cited by 6
Nicotine alleviates colitis-induced damage in rats via its anti-oxidative activity
Kumral, Z. N. Ö., Tazegül, G., Bektaşoğlu, P. K., Bilgin, S., MENTEŞE, S. T., Erzık, C., Şirvancı, S., & Yeğen, B. Ç. (2014) · Marmara medical journal · doi:10.5472/mmj.2013.03125.1 · Cited by 6
“Epidemiological studies have shown that there was a distinct lack of current smokers in a cohort of UC patients when matched with control subjects [3, 31], while UC patients with a smoking history usually acquire their disease within 1 or 2 years after they have quit smoking [32-34].”
Pavlov, V. A., Ulloa, L., & Metz, C. N. (2010) · Neuroimmune biology · doi:10.1016/s1567-7443(10)70027-2 · Cited by 7
Evolution of acupuncture for pain management
Kim, D. H. (2004) · Seminars in Integrative Medicine · doi:10.1016/j.sigm.2005.01.003 · Cited by 6
Iskandar, H. N., Greer, J. B., Schraut, W. H., Regueiro, M. D., Davis, P. L., Hartman, D. J., Siegel, C. A., Herfarth, H. H., Williams, E., & Schwartz, M. B. (2014) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000188 · Cited by 6
Dangerous plants in dermatology: Legal and controlled
Singh, D., Fisher, J., Shagalov, D. R., Varma, A., & Siegel, D. M. (2018) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2018.03.013 · Cited by 6
Can incoagulable blood protect against inflammatory bowel disease?
Langman, M. J. S. (1995) · Gastroenterology · doi:10.1016/0016-5085(95)90233-3 · Cited by 6
Less Commonly Used Therapies for IBD or Treatments on the Fringe
Burakoff, R. B. (1998) · Inflammatory Bowel Diseases · doi:10.1002/ibd.3780040410 · Cited by 6
Taylor, K. D., Yang, H., & Rotter, J. I. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-383834-6.00072-0 · Cited by 6
Medical Therapy of Ulcerative Proctitis and Proctosigmoiditis, Including Refractory Disease
Bitton, A., & Peppercorn, M. A. (1995) · Inflammatory Bowel Diseases · doi:10.1002/ibd.3780010308 · Cited by 6
Loftus, E. V. (2007) · Wiley eBooks · doi:10.1002/9780470692189.ch27 · Cited by 6
Hua, X., Lopes, E. W., Burke, K. E., Ananthakrishnan, A. N., Richter, J. M., Lo, C., Lochhead, P. J., Chan, A. T., & Khalili, H. (2022) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjac015 · Cited by 7
Xu, C., Nery, P. B., Wiefels, C., Beanlands, R. S., Spence, S., Juneau, D., Promislow, S., Boczar, K. E., deKemp, R. A., & Birnie, D. H. (2022) · CJC Open · doi:10.1016/j.cjco.2022.06.001 · Cited by 5
“Evidence does suggest that smoking may reduce macrophage activation post-dust exposure.(15,17) Smoking may also exert its protective effects through lymphocyte modulation, as studies have shown that lymphocyte activation may be associated with pulmonary sarcoidosis.”
BackgroundKondo, K., Ono, Y., Ohfuji, S., Watanabe, K., Yamagami, H., Watanabe, M., Nishiwaki, Y., Fukushima, W., Hirota, Y., Suzuki, Y., et al. (2022) · JGH Open · doi:10.1002/jgh3.12857 · Cited by 5
Traitement de la rectocolite ulcéro-hémorragique dans sa forme distale
Seksik, P., Contou, J. F., Ducrotte, P. R., Faucheron, J., & de Parades, V. (2004) · Gastroentérologie Clinique et Biologique · doi:10.1016/s0399-8320(04)95174-3 · Cited by 4
“Parmi les essais contrôlés, deux ont démontré une efficacité de la nicotine supérieure au placebo [102, 103] alors que d’autres ont été négatifs [104].”
Vrablicova, Z., Šoltýs, K., Krajčovičová, A., STUCHLIKOVA, K., Šturdík, I., Koller, T., Huorka, M., Payer, J., Killinger, Z., Jackuliak, P., et al. (2019) · Physiological Research · doi:10.33549/physiolres.934301 · Cited by 5
Abdrakhmanova, G. R., Kang, M., Damaj, M. I., & Akbarali, H. I. (2012) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00411.2011 · Cited by 5
“Although controlled clinical trials indicate that transdermal nicotine patch significantly improves the histological and global clinical score of colitis, including abdominal pain (25, 34), the in vivo actions of nicotine in colonic inflammation are not well characterized.”
BackgroundShort-term treatment with transdermal nicotine affects the function of canine saphenous veins
Clouse, W. D., Rud, K. S., Hurt, R. D., & Miller, V. M. (2000) · Vascular Medicine · doi:10.1177/1358836x0000500203 · Cited by 5
Concepts in Inflammatory Bowel Disease Management
Messaris, E., & Dassopoulos, T. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-40232-3.00161-8 · Cited by 4
Deng, P., Peng, Y., Pei, C., Li, X., Wu, J., & Zhang, S. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-058973 · Cited by 4
Can a gluten‐free diet be partly protective for COVID‐19 infection?
Haupt‐Jorgensen, M., & Buschard, K. (2020) · Apmis · doi:10.1111/apm.13075 · Cited by 4
“Of note, nicotine is also associated with protection from ulcerative colitis [6], as well as other autoimmune diseases [7].”
BackgroundNicotine: therapeutic potential for the treatment of ulcerative colitis
Green, J. T., Thomas, G. A. O., & Rhodes, J. (1997) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.6.1.17 · Cited by 4
Self-citationNicotine InhibitsClostridium difficileToxin A-Induced Colitis but Not Ileitis in Rats
Vigna, S. R. (2016) · International Journal of Inflammation · doi:10.1155/2016/4705065 · Cited by 4
“Nicotine has been shown to be the active protective component in tobacco smoke because nicotine transdermal patches or nicotine enemas protect the colon in UC [6, 7].”
BackgroundCOMPLEMENTARY MEDICINE USE BY PATIENTS WITH INFLAMMATORY BOWEL DISEASE
Katz, J., & Weinberg, L. (1998) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1998.673_a.x · Cited by 4
“Seventeen patients in the nicotine group had complete remissions, as compared with nine of the 37 patients in the placebo group”
ResultUpdate in Medical Therapy in Inflammatory Bowel Disease: A Clinician’s View
Katz, S. (1999) · Digestive Diseases · doi:10.1159/000016921 · Cited by 4
Recent developments in inflammatory bowel disease therapy
Murthy, S., & Flanigan, A. (1997) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.7.7.695 · Cited by 4
A 66-Year-Old Woman With Ulcerative Colitis
Peppercorn, M. A. (1998) · JAMA · doi:10.1001/jama.279.12.949 · Cited by 4
Lifestyle Issues in Inflammatory Bowel Disease – Smoking
Benoni, C. (1994) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/1994/369127 · Cited by 4
Therapeutic Approaches to the Treatment of Ulcerative Colitis
Sandborn, W. J. (2010) · Wiley eBooks · doi:10.1002/9781444318418.ch28 · Cited by 5
Kobayashi, T., Dignass, A. U., Roblin, X., Takatori, Y., Kaise, T., Oortwijn, A. F., Jamoul, C., & Hibi∥, T. (2024) · Intestinal Research · doi:10.5217/ir.2024.00007 · Cited by 3
“20,21 Smoking cessation is encouraged for general health in patients with UC.”
BackgroundMeta‐Analysis: Improvement of Bowel Urgency With Advanced Therapies for Inflammatory Bowel Disease
Patel, P., Belesiotis, P., Rai, N. S., Yuan, Y.-H., Narula, N., Ma, C., Cino, M., Sasson, A., Jairath, V., & Tandon, P. (2025) · Alimentary Pharmacology and Therapeutics · doi:10.1111/apt.70446 · Cited by 3
Effect of Some Storage Conditions upon the Survival of Some Fungal Spores
Al-Shikli, R. A., Abdulrasool, A. A., & Al-Hiti, M. M. (2017) · Iraqi Journal of Pharmaceutical Sciences · doi:10.31351/vol19iss2pp1-10 · Cited by 3
Transdermal nicotine in non-smokers: A systematic review to design COVID-19 clinical trials
Dautzenberg, B., Levi, A., Adler, M., & Raphaël Gaillard, B. (2021) · Respiratory Medicine and Research · doi:10.1016/j.resmer.2021.100844 · Cited by 3
Influence of Polymeric Blend of Carbomer-Gum on the Targeted Delivery of 5-FU
Sinha, V. R., Kumar, R., & Bhinge, J. R. (2009) · Polymer-Plastics Technology and Engineering · doi:10.1080/03602550903204154 · Cited by 3
“On ingestion of a suitably formulated solid oral dosage form, carbomers hydrate and swell to form a gel, which further retards drug release and absorption and serve as excellent topical or local delivery vehicles for bioactive compounds([6]).”
BackgroundNovel treatments in inflammatory bowel disease
Pathmakanthan, S., & Stack, W. A. (1999) · Hospital Medicine · doi:10.12968/hosp.1999.60.1.1019 · Cited by 3
Frenk, H., & Dar, R. (2011) · Harm Reduction Journal · doi:10.1186/1477-7517-8-12 · Cited by 4
“While such an experiment sounds ethically dubious, it has been in fact performed [94].”
BackgroundKornbluth, A. A., & Sachar, D. B. (2004) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2004.40036.x · Cited by 5
“Controlled trials have demonstrated that transdermal nicotine patches are effective in achieving clinical improvement (66) and clinical remission (67) in patients with mildmoderate UC, with a dose-response effect between 15 and 25 mg of nicotine daily, but their success rates are generally lower than with traditional…”
BackgroundMedikamentöse Therapie der Colitis ulcerosa
Adler, G. (1993) · Springer eBooks · doi:10.1007/978-3-642-97440-3_18 · Cited by 3
Travis, S. P. L. (2006) · Wiley eBooks · doi:10.1002/9780470753170.ch10 · Cited by 3
Smoking and Chronic Inflammatory Bowel Disease
Osborne, M. J., & Stansby, G. P. (1994) · Journal of the Royal Society of Health · doi:10.1177/146642409411400609 · Cited by 3
Clinical perspectives in inflammatory bowel disease
Selby, W. S. (1996) · Australian and New Zealand Journal of Medicine · doi:10.1111/j.1445-5994.1996.tb02901.x · Cited by 3
Etiopatogenia de la enfermedad inflamatoria del tubo digestivo
de Tena, J. G., Espinosa, L. M., Berral, J. C. L., & Soto, M. L.-M. (2004) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0211-3449(04)70038-7 · Cited by 3
Chowers, Y. (2002) · PubMed · Cited by 3
New concepts of pathogenesis in IBD
Fiocchi, C. (1994) · Springer eBooks · doi:10.1007/978-94-009-0371-5_25 · Cited by 3
Hasegawa, M., Kawaguchi, T., Kiyohara, H., Teratani, T., Nakamoto, N., Mikami, Y., & Kanai, T. (2025) · Immunological Medicine · doi:10.1080/25785826.2025.2604347 · Cited by 2
“…is mainly mucosal and characterized by a Th2-like cytokine profile, activation of α7nAChR on immune and epithelial cells can more effectively suppress inflammatory cytokine production and support barrier function, consistent with the modest benefits observed in nicotine treatment trials [71].”
Metadata
- Authors
- Pullan, R. D., Rhodes, J., Ganesh, S., Mani, V., Morris, J. S., Williams, G. T., Newcombe, R. G., Russell, M., Feyerabend, C., Thomas, G., & Sawe, U.
- Affiliations
- University Hospital of Wales (GB)
- University of Wales (GB)
- Princess of Wales Hospital (GB)
- New Cross Hospital (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1994-03-24
- Volume
- 330
- Issue
- 12
- Pages
- 811-815
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2315418290
- Cited by
- 505
- References
- 28
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 9 · 2023: 11 · 2022: 10 · 2021: 10 · 2020: 20 · 2019: 9 · 2018: 14 · 2017: 7 · 2016: 5 · 2015: 11 · 2014: 14 · 2013: 15 · 2012: 9
- FWCI
- 15.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
- Health Sciences › Medicine › Gastroenterology › Microscopic Colitis
- Keywords
- ulcerative colitis, transdermal nicotine, nicotine patch, smoking, nicotine withdrawal, 5-aminosalicylic acid, maintenance therapy, remission, symptom improvement, adverse effects
- MeSH terms
- Administration, Cutaneous, Adult, Affect, Colitis, Ulcerative, Cotinine, Double-Blind Method, Female, Humans, Male, Middle Aged, Nicotine, Treatment Outcome, Drug Monitoring
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
